Laboratorios Farmaceuticos Rovi (XMAD:ROVI) 3-Year Book Growth Rate : 15.60% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi 3-Year Book Growth Rate?

Laboratorios Farmaceuticos Rovi's Book Value per Share for the quarter that ended in Dec. 2023 was €10.41.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Book Value per Share Growth Rate was 4.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was 15.60% per year. During the past 5 years, the average Book Value per Share Growth Rate was 16.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Laboratorios Farmaceuticos Rovi was 50.20% per year. The lowest was 6.80% per year. And the median was 15.80% per year.

Competitive Comparison of Laboratorios Farmaceuticos Rovi's 3-Year Book Growth Rate

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 3-Year Book Growth Rate falls into.

Laboratorios Farmaceuticos Rovi 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Laboratorios Farmaceuticos Rovi 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.